SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Trial Profile

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 Results (n=86) assessing safety and activity of immune checkpoint blockade with pembrolizumab in patients with advanced soft-tissue sarcoma or bone sarcoma, were published in the Lancet Oncology.
    • 06 Jun 2017 Results (n=86) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 30 May 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top